Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: CBFA2T2 (ImmuneEditome ID:9139)

1. Gene summary of enriched editing regions for CBFA2T2

Gene summary

Gene information	Gene symbol	CBFA2T2
	Gene ID	9139
	GeneSynonyms	EHT\|MTGR1\|ZMYND3\|p85
	GeneCytomap	20q11.21-q11.22
	GeneType	protein-coding
	GeneDescription	protein CBFA2T2\|CBFA2/RUNX1 translocation partner 2\|ETO homolog on chromosome 20\|ETO homologous on chromosome 20\|MTG8-like protein\|MTG8-related protein 1\|core-binding factor, runt domain, alpha subunit 2; translocated to, 2\|myeloid translocation gene-related protein 1\|myeloid translocation-related protein 1
	GeneModificationdate	20230329
	UniprotID	O43439;Q68DC6
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr20:33495138-33495587:+	ENST00000471007.1	ENSG00000078699.20	CBFA2T2	ncRNA_intronic	AluSx3,AluSq2	chr20:33495138-33495587:+.alignment
chr20:33502520-33502983:+	ENST00000471007.1	ENSG00000078699.20	CBFA2T2	ncRNA_intronic	L1MC4,AluY	chr20:33502520-33502983:+.alignment
chr20:33509197-33509758:+	ENST00000471007.1	ENSG00000078699.20	CBFA2T2	ncRNA_intronic	AluSx,AluSx1	chr20:33509197-33509758:+.alignment
chr20:33511857-33513812:+	ENST00000471007.1	ENSG00000078699.20	CBFA2T2	ncRNA_intronic	AluSg,AluSz,AluSz6,AluSx1,AluY,L1ME3A	chr20:33511857-33513812:+.alignment
chr20:33515631-33516065:+	ENST00000471007.1	ENSG00000078699.20	CBFA2T2	ncRNA_intronic	AluJo,AluSg	chr20:33515631-33516065:+.alignment
chr20:33518600-33520634:+	ENST00000471007.1	ENSG00000078699.20	CBFA2T2	ncRNA_intronic	MER2,AluSx,AluSz,MER5A,AluSp	chr20:33518600-33520634:+.alignment
chr20:33529543-33530606:+	ENST00000471007.1	ENSG00000078699.20	CBFA2T2	ncRNA_intronic	(TA)n,AluSz,FLAM_C,AluJo,AluSq	chr20:33529543-33530606:+.alignment
chr20:33611541-33611726:+	ENST00000471007.1	ENSG00000078699.20	CBFA2T2	ncRNA_intronic	AluJr	chr20:33611541-33611726:+.alignment
chr20:33633184-33635693:+	ENST00000491618.1	ENSG00000078699.20	CBFA2T2	ncRNA_intronic	AluSz6,AluJr4,MERX,AluJb,AluSg,(AAAT)n,(TATTA)n,L1ME3B,HAL1	chr20:33633184-33635693:+.alignment
chr20:33642463-33643514:+	ENST00000342704.9	ENSG00000078699.20	CBFA2T2	intronic	AluJb,AluJr,MIR3,(TATCTG)n,MIR	chr20:33642463-33643514:+.alignment
chr20:33642463-33643514:+	ENST00000346541.6	ENSG00000078699.20	CBFA2T2	intronic	AluJb,AluJr,MIR3,(TATCTG)n,MIR	chr20:33642463-33643514:+.alignment
chr20:33642463-33643514:+	ENST00000359606.3	ENSG00000078699.20	CBFA2T2	intronic	AluJb,AluJr,MIR3,(TATCTG)n,MIR	chr20:33642463-33643514:+.alignment
chr20:33642463-33643514:+	ENST00000375279.5	ENSG00000078699.20	CBFA2T2	intronic	AluJb,AluJr,MIR3,(TATCTG)n,MIR	chr20:33642463-33643514:+.alignment
chr20:33642463-33643514:+	ENST00000397800.4	ENSG00000078699.20	CBFA2T2	intronic	AluJb,AluJr,MIR3,(TATCTG)n,MIR	chr20:33642463-33643514:+.alignment
chr20:33642463-33643514:+	ENST00000492345.4	ENSG00000078699.20	CBFA2T2	intronic	AluJb,AluJr,MIR3,(TATCTG)n,MIR	chr20:33642463-33643514:+.alignment
chr20:33642463-33643514:+	ENST00000543126.1	ENSG00000078699.20	CBFA2T2	intronic	AluJb,AluJr,MIR3,(TATCTG)n,MIR	chr20:33642463-33643514:+.alignment
chr20:33645986-33647601:+	ENST00000346541.6	ENSG00000078699.20	CBFA2T2	UTR3	AluSz,AluSp,AluSx1	chr20:33645986-33647601:+.alignment
chr20:33645986-33647601:+	ENST00000359606.3	ENSG00000078699.20	CBFA2T2	UTR3	AluSz,AluSp,AluSx1	chr20:33645986-33647601:+.alignment
chr20:33645986-33647601:+	ENST00000375279.5	ENSG00000078699.20	CBFA2T2	UTR3	AluSz,AluSp,AluSx1	chr20:33645986-33647601:+.alignment
chr20:33645986-33647601:+	ENST00000397800.4	ENSG00000078699.20	CBFA2T2	UTR3	AluSz,AluSp,AluSx1	chr20:33645986-33647601:+.alignment
chr20:33645986-33647601:+	ENST00000492345.4	ENSG00000078699.20	CBFA2T2	UTR3	AluSz,AluSp,AluSx1	chr20:33645986-33647601:+.alignment
chr20:33645986-33647601:+	ENST00000543126.1	ENSG00000078699.20	CBFA2T2	UTR3	AluSz,AluSp,AluSx1	chr20:33645986-33647601:+.alignment

Top

2. Tumor-specific enriched editing regions for CBFA2T2

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr20:33645986-33647601:+	COAD	EER	5.4780e-04
ENSG00000078699.20,CBFA2T2	COAD	EAG	7.7377e-05
chr20:33645986-33647601:+	KIRC	EER	1.2812e-02
ENSG00000078699.20,CBFA2T2	KIRC	EAG	6.9833e-03
chr20:33645986-33647601:+	KIRP	EER	1.3838e-02
ENSG00000078699.20,CBFA2T2	KIRP	EAG	1.0520e-02
chr20:33645986-33647601:+	LUSC	EER	4.7604e-02
ENSG00000078699.20,CBFA2T2	LUSC	EAG	4.6423e-02
chr20:33645986-33647601:+	THCA	EER	6.0970e-06
ENSG00000078699.20,CBFA2T2	THCA	EAG	2.8238e-06

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000078699.20,CBFA2T2	ESCA	Path	EAG	1.6975e-02	3.8910e-02	0.1729
chr20:33645986-33647601:+	THCA	Path	EER	7.2781e-03	4.6467e-02	0.0939
ENSG00000078699.20,CBFA2T2	THCA	Path	EAG	4.9633e-02	3.2687e-02	0.1005

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr20:33645986-33647601:+	HNSC	EER	8.2050e-03	4.5911e-02	1.5116e+01
ENSG00000078699.20,CBFA2T2	HNSC	EAG	8.2050e-03	4.5717e-02	1.5154e+01
chr20:33515631-33516065:+	STAD	EER	3.8405e-05	8.6934e-04	8.6065e+04
chr20:33645986-33647601:+	UCEC	EER	4.7753e-02	3.8970e-02	1.6888e+02

Top

3. Enriched editing regions and immune related genes for CBFA2T2

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr20:33645986-33647601:+

STAD

EER

ENSG00000152102,FAM168B

-0.4259

4.3625e-13

2.6163e-16

-0.4110

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_CD8

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr20:33645986-33647601:+

STAD

EER

ENSG00000182117,NOP10

0.4170

1.3832e-12

1.1691e-16

0.4154

ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

B_cells_naive

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr20:33645986-33647601:+

UCEC

EER

ENSG00000038358,EDC4

-0.4657

2.2457e-04

5.7505e-07

-0.4249

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_follicular_helper

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000181090,EHMT1

-0.4546

3.0464e-04

7.5699e-07

-0.4208

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

Plasma_cells

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000161021,MAML1

-0.4494

4.4819e-04

5.8279e-07

-0.4247

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000130723,PRRC2B

-0.4490

4.6810e-04

1.3815e-06

-0.4117

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

PRRC2B

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000215301,DDX3X

-0.4312

9.1154e-04

3.2210e-07

-0.4334

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

DDX3X

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000144560,VGLL4

-0.4229

1.2482e-03

1.7668e-06

-0.4078

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_CD8

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000178127,NDUFV2

0.4216

1.2887e-03

2.4399e-07

0.4374

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

B_cells_naive

GSVA_HALLMARK_UV_RESPONSE_DN

chr20:33645986-33647601:+

UCEC

EER

ENSG00000102931,ARL2BP

-0.4165

1.5170e-03

1.0476e-06

-0.4159

CELF2;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

STAD

EER

ENSG00000152102,FAM168B

-0.4259

4.3625e-13

2.6163e-16

-0.4110

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_CD8

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr20:33645986-33647601:+

STAD

EER

ENSG00000182117,NOP10

0.4170

1.3832e-12

1.1691e-16

0.4154

ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

B_cells_naive

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr20:33645986-33647601:+

UCEC

EER

ENSG00000038358,EDC4

-0.4657

2.2457e-04

5.7505e-07

-0.4249

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_follicular_helper

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000181090,EHMT1

-0.4546

3.0464e-04

7.5699e-07

-0.4208

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

Plasma_cells

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000161021,MAML1

-0.4494

4.4819e-04

5.8279e-07

-0.4247

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000130723,PRRC2B

-0.4490

4.6810e-04

1.3815e-06

-0.4117

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

PRRC2B

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000215301,DDX3X

-0.4312

9.1154e-04

3.2210e-07

-0.4334

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

DDX3X

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000144560,VGLL4

-0.4229

1.2482e-03

1.7668e-06

-0.4078

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_CD8

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000178127,NDUFV2

0.4216

1.2887e-03

2.4399e-07

0.4374

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

B_cells_naive

GSVA_HALLMARK_UV_RESPONSE_DN

chr20:33645986-33647601:+

UCEC

EER

ENSG00000102931,ARL2BP

-0.4165

1.5170e-03

1.0476e-06

-0.4159

CELF2;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

STAD

EER

ENSG00000152102,FAM168B

-0.4259

4.3625e-13

2.6163e-16

-0.4110

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_CD8

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr20:33645986-33647601:+

STAD

EER

ENSG00000182117,NOP10

0.4170

1.3832e-12

1.1691e-16

0.4154

ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

B_cells_naive

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr20:33645986-33647601:+

UCEC

EER

ENSG00000038358,EDC4

-0.4657

2.2457e-04

5.7505e-07

-0.4249

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_follicular_helper

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000181090,EHMT1

-0.4546

3.0464e-04

7.5699e-07

-0.4208

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

Plasma_cells

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000161021,MAML1

-0.4494

4.4819e-04

5.8279e-07

-0.4247

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000130723,PRRC2B

-0.4490

4.6810e-04

1.3815e-06

-0.4117

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

PRRC2B

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000215301,DDX3X

-0.4312

9.1154e-04

3.2210e-07

-0.4334

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

DDX3X

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000144560,VGLL4

-0.4229

1.2482e-03

1.7668e-06

-0.4078

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_CD8

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000178127,NDUFV2

0.4216

1.2887e-03

2.4399e-07

0.4374

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

B_cells_naive

GSVA_HALLMARK_UV_RESPONSE_DN

chr20:33645986-33647601:+

UCEC

EER

ENSG00000102931,ARL2BP

-0.4165

1.5170e-03

1.0476e-06

-0.4159

CELF2;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

STAD

EER

ENSG00000152102,FAM168B

-0.4259

4.3625e-13

2.6163e-16

-0.4110

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_CD8

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr20:33645986-33647601:+

STAD

EER

ENSG00000182117,NOP10

0.4170

1.3832e-12

1.1691e-16

0.4154

ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

B_cells_naive

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr20:33645986-33647601:+

UCEC

EER

ENSG00000038358,EDC4

-0.4657

2.2457e-04

5.7505e-07

-0.4249

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_follicular_helper

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000181090,EHMT1

-0.4546

3.0464e-04

7.5699e-07

-0.4208

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

Plasma_cells

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000161021,MAML1

-0.4494

4.4819e-04

5.8279e-07

-0.4247

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000130723,PRRC2B

-0.4490

4.6810e-04

1.3815e-06

-0.4117

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

PRRC2B

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000215301,DDX3X

-0.4312

9.1154e-04

3.2210e-07

-0.4334

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

DDX3X

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000144560,VGLL4

-0.4229

1.2482e-03

1.7668e-06

-0.4078

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_CD8

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000178127,NDUFV2

0.4216

1.2887e-03

2.4399e-07

0.4374

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

B_cells_naive

GSVA_HALLMARK_UV_RESPONSE_DN

chr20:33645986-33647601:+

UCEC

EER

ENSG00000102931,ARL2BP

-0.4165

1.5170e-03

1.0476e-06

-0.4159

CELF2;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

STAD

EER

ENSG00000152102,FAM168B

-0.4259

4.3625e-13

2.6163e-16

-0.4110

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_CD8

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr20:33645986-33647601:+

STAD

EER

ENSG00000182117,NOP10

0.4170

1.3832e-12

1.1691e-16

0.4154

ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

B_cells_naive

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr20:33645986-33647601:+

UCEC

EER

ENSG00000038358,EDC4

-0.4657

2.2457e-04

5.7505e-07

-0.4249

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_follicular_helper

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000181090,EHMT1

-0.4546

3.0464e-04

7.5699e-07

-0.4208

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

Plasma_cells

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000161021,MAML1

-0.4494

4.4819e-04

5.8279e-07

-0.4247

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000130723,PRRC2B

-0.4490

4.6810e-04

1.3815e-06

-0.4117

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

PRRC2B

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000215301,DDX3X

-0.4312

9.1154e-04

3.2210e-07

-0.4334

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

DDX3X

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000144560,VGLL4

-0.4229

1.2482e-03

1.7668e-06

-0.4078

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_CD8

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000178127,NDUFV2

0.4216

1.2887e-03

2.4399e-07

0.4374

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

B_cells_naive

GSVA_HALLMARK_UV_RESPONSE_DN

chr20:33645986-33647601:+

UCEC

EER

ENSG00000102931,ARL2BP

-0.4165

1.5170e-03

1.0476e-06

-0.4159

CELF2;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

STAD

EER

ENSG00000152102,FAM168B

-0.4259

4.3625e-13

2.6163e-16

-0.4110

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_CD8

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr20:33645986-33647601:+

STAD

EER

ENSG00000182117,NOP10

0.4170

1.3832e-12

1.1691e-16

0.4154

ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

B_cells_naive

GSVA_HALLMARK_HEDGEHOG_SIGNALING

chr20:33645986-33647601:+

UCEC

EER

ENSG00000038358,EDC4

-0.4657

2.2457e-04

5.7505e-07

-0.4249

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_follicular_helper

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000181090,EHMT1

-0.4546

3.0464e-04

7.5699e-07

-0.4208

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

Plasma_cells

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000161021,MAML1

-0.4494

4.4819e-04

5.8279e-07

-0.4247

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000130723,PRRC2B

-0.4490

4.6810e-04

1.3815e-06

-0.4117

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

PRRC2B

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000215301,DDX3X

-0.4312

9.1154e-04

3.2210e-07

-0.4334

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

DDX3X

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000144560,VGLL4

-0.4229

1.2482e-03

1.7668e-06

-0.4078

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_CD8

GSVA_HALLMARK_MITOTIC_SPINDLE

chr20:33645986-33647601:+

UCEC

EER

ENSG00000178127,NDUFV2

0.4216

1.2887e-03

2.4399e-07

0.4374

CELF2;DKC1;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

B_cells_naive

GSVA_HALLMARK_UV_RESPONSE_DN

chr20:33645986-33647601:+

UCEC

EER

ENSG00000102931,ARL2BP

-0.4165

1.5170e-03

1.0476e-06

-0.4159

CELF2;ELAVL1;HNRNPK;IGF2BP2;NOP56;NOP58;PTBP1;SRSF3;TARDBP;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

More results

Top

4. Enriched editing regions and immune related splicing for CBFA2T2

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000078699.20,CBFA2T2

CESC

EAG

MEX

ENSG00000101294.12

chr20

31554746:31554829:31559610:31559647:31566209:31566295:31569119:31569174

-0.3359

2.8351e-04

1.6974e-11

-0.4151

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YTHDF2;YWHAG;ZNF184

HM13

B_cells_naive

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000078699.20,CBFA2T2

CESC

EAG

MEX

ENSG00000109919.5

chr11

47627079:47627127:47628952:47629023:47631035:47631087:47631653:47631711

0.3300

3.4663e-04

4.9739e-14

0.4593

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

B_cells_memory

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000078699.20,CBFA2T2

CESC

EAG

ENSG00000136485.10

chr17

63588999:63589237:63594202:63594259

-0.3225

4.4016e-04

7.0297e-11

-0.4033

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

B_cells_naive

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000078699.20,CBFA2T2

CESC

EAG

MEX

ENSG00000198755.6

chr6

35468946:35469027:35469380:35469529:35470324:35470351:35470579:35470640

-0.2997

2.4991e-03

2.4914e-12

-0.4303

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

B_cells_memory

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000078699.20,CBFA2T2

CESC

EAG

MEX

ENSG00000188313.8

chr3

146517157:146517167:146521543:146522053:146528613:146528831:146533469:146533550

0.2909

3.5698e-03

7.3002e-11

0.4030

ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM22;RBM27;RBM47;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZNF184

PLSCR1

B_cells_naive

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000078699.20,CBFA2T2

CESC

EAG

MEX

ENSG00000105438.4

chr19

48382577:48383327:48384229:48384367:48384422:48384482:48389552:48389711

0.2833

6.9658e-03

2.7348e-11

0.4112

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

B_cells_memory

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000078699.20,CBFA2T2

CESC

EAG

ENSG00000136448.7

chr17

45105764:45105945:45107778:45108134

-0.2775

9.2050e-03

2.5744e-11

-0.4117

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

B_cells_memory

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000078699.20,CBFA2T2

CESC

EAG

MEX

ENSG00000102144.9

chrX

78118144:78118170:78122834:78122902:78124873:78125051:78125326:78125425

-0.2706

1.1680e-02

2.4604e-12

-0.4304

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

B_cells_memory

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000078699.20,CBFA2T2

CESC

EAG

MEX

ENSG00000071553.12

chrX

154431829:154431904:154432265:154432376:154433659:154433720:154434207:154434219

-0.2700

1.3532e-02

2.5139e-12

-0.4303

ACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YTHDF2;YWHAG;ZNF184

B_cells_memory

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000078699.20,CBFA2T2

CESC

EAG

MEX

ENSG00000068912.9

chr2

53797731:53797795:53799046:53799081:53808298:53808460:53809213:53809273

-0.2682

1.4328e-02

4.1332e-11

-0.4077

ACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184

B_cells_memory

GSVA_HALLMARK_MITOTIC_SPINDLE

More results

Top

5. Enriched editing regions and immune infiltration for CBFA2T2

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr20:33645986-33647601:+	ACC	EER	T_cells_CD4_naive	2.7901e-02	0.4911
ENSG00000078699.20,CBFA2T2	ACC	EAG	T_cells_CD4_naive	2.7901e-02	0.4911
chr20:33645986-33647601:+	BRCA	EER	NK_cells_activated	1.2524e-05	0.1381
ENSG00000078699.20,CBFA2T2	BRCA	EAG	NK_cells_activated	2.5093e-05	0.1332
chr20:33645986-33647601:+	CESC	EER	B_cells_memory	5.8087e-04	0.2205
ENSG00000078699.20,CBFA2T2	CESC	EAG	B_cells_memory	8.1883e-04	0.2137
chr20:33645986-33647601:+	CHOL	EER	Dendritic_cells_activated	4.8162e-03	-0.5355
ENSG00000078699.20,CBFA2T2	CHOL	EAG	Dendritic_cells_activated	4.8162e-03	-0.5355
chr20:33645986-33647601:+	COAD	EER	Mast_cells_activated	1.8728e-03	0.1954
ENSG00000078699.20,CBFA2T2	COAD	EAG	Mast_cells_activated	1.4351e-06	0.2970
chr20:33515631-33516065:+	ESCA	EER	Macrophages_M0	3.9367e-02	0.3357
chr20:33645986-33647601:+	ESCA	EER	T_cells_regulatory_(Tregs)	3.1797e-04	-0.2802
ENSG00000078699.20,CBFA2T2	ESCA	EAG	T_cells_regulatory_(Tregs)	3.6304e-04	-0.2776
chr20:33645986-33647601:+	GBM	EER	Dendritic_cells_activated	2.5378e-02	-0.1931
ENSG00000078699.20,CBFA2T2	GBM	EAG	Dendritic_cells_activated	2.5378e-02	-0.1931
chr20:33645986-33647601:+	HNSC	EER	B_cells_naive	1.6941e-03	-0.1670
ENSG00000078699.20,CBFA2T2	HNSC	EAG	B_cells_naive	1.1205e-03	-0.1730
chr20:33645986-33647601:+	KICH	EER	Dendritic_cells_resting	1.1816e-02	0.3342
ENSG00000078699.20,CBFA2T2	KICH	EAG	Dendritic_cells_resting	1.1816e-02	0.3342
chr20:33645986-33647601:+	KIRC	EER	Macrophages_M0	2.0098e-02	0.1316
ENSG00000078699.20,CBFA2T2	KIRC	EAG	Plasma_cells	3.0825e-02	0.1221
ENSG00000078699.20,CBFA2T2	KIRP	EAG	T_cells_CD8	7.4618e-03	0.1820
chr20:33645986-33647601:+	LAML	EER	T_cells_regulatory_(Tregs)	1.1209e-02	0.2337
ENSG00000078699.20,CBFA2T2	LAML	EAG	Monocytes	1.9187e-02	0.2068
chr20:33645986-33647601:+	LGG	EER	Dendritic_cells_resting	2.0093e-04	0.1700
ENSG00000078699.20,CBFA2T2	LGG	EAG	Dendritic_cells_resting	2.0093e-04	0.1700
chr20:33645986-33647601:+	MESO	EER	Dendritic_cells_resting	1.4683e-03	-0.4555
ENSG00000078699.20,CBFA2T2	MESO	EAG	Dendritic_cells_resting	1.4683e-03	-0.4555
chr20:33645986-33647601:+	OV	EER	B_cells_memory	3.2201e-04	0.2127
ENSG00000078699.20,CBFA2T2	OV	EAG	B_cells_memory	1.5716e-04	0.2232
chr20:33645986-33647601:+	PAAD	EER	T_cells_CD4_memory_resting	1.3227e-02	-0.2211
ENSG00000078699.20,CBFA2T2	PAAD	EAG	T_cells_CD4_memory_resting	1.3227e-02	-0.2211
chr20:33645986-33647601:+	PCPG	EER	B_cells_memory	4.5393e-06	0.3817
ENSG00000078699.20,CBFA2T2	PCPG	EAG	B_cells_memory	4.5393e-06	0.3817
chr20:33645986-33647601:+	PRAD	EER	T_cells_CD4_memory_resting	3.4424e-02	-0.0985
ENSG00000078699.20,CBFA2T2	PRAD	EAG	T_cells_CD4_memory_resting	1.3302e-02	-0.1145
chr20:33645986-33647601:+	READ	EER	Eosinophils	8.1713e-03	-0.2742
ENSG00000078699.20,CBFA2T2	READ	EAG	Eosinophils	1.4062e-02	-0.2539
chr20:33645986-33647601:+	SARC	EER	T_cells_CD4_memory_activated	1.3509e-02	0.1804
ENSG00000078699.20,CBFA2T2	SARC	EAG	T_cells_CD4_memory_activated	1.3509e-02	0.1804
chr20:33645986-33647601:+	SKCM	EER	Dendritic_cells_activated	1.2893e-05	0.2141
ENSG00000078699.20,CBFA2T2	SKCM	EAG	Dendritic_cells_activated	1.2893e-05	0.2141
chr20:33509197-33509758:+	STAD	EER	Monocytes	2.6434e-02	-0.3553
chr20:33515631-33516065:+	STAD	EER	Plasma_cells	4.6619e-02	0.2165
chr20:33518600-33520634:+	STAD	EER	Monocytes	3.2597e-02	-0.3728
chr20:33633184-33635693:+	STAD	EER	Dendritic_cells_activated	3.8415e-03	0.3803
chr20:33645986-33647601:+	STAD	EER	T_cells_CD4_memory_resting	2.9824e-03	-0.1550
ENSG00000078699.20,CBFA2T2	STAD	EAG	T_cells_CD4_memory_resting	2.6469e-03	-0.1569
chr20:33645986-33647601:+	TGCT	EER	Mast_cells_resting	4.4812e-04	0.2859
ENSG00000078699.20,CBFA2T2	TGCT	EAG	Mast_cells_resting	4.5581e-04	0.2855
chr20:33645986-33647601:+	THCA	EER	T_cells_follicular_helper	6.5336e-03	0.1279
ENSG00000078699.20,CBFA2T2	THCA	EAG	Plasma_cells	3.4247e-04	0.1675
chr20:33645986-33647601:+	THYM	EER	T_cells_CD4_memory_activated	4.5705e-05	0.4445
ENSG00000078699.20,CBFA2T2	THYM	EAG	T_cells_CD4_memory_activated	2.2363e-04	0.4038
chr20:33645986-33647601:+	UCEC	EER	T_cells_regulatory_(Tregs)	4.3298e-03	0.2506
ENSG00000078699.20,CBFA2T2	UCEC	EAG	T_cells_regulatory_(Tregs)	9.7752e-03	0.2258
chr20:33645986-33647601:+	UVM	EER	Mast_cells_activated	2.4235e-05	0.5408
ENSG00000078699.20,CBFA2T2	UVM	EAG	Mast_cells_activated	2.4235e-05	0.5408

Top

6. Enriched editing regions and immune gene sets for CBFA2T2

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
ENSG00000078699.20,CBFA2T2	HNSC	EAG	1.4242e-02	0.1306	1.0021e-04	-0.2058	1.8724e-02	0.1253	9.9364e-03	0.1372
chr20:33645986-33647601:+	HNSC	EER	9.3055e-03	0.1386	3.8377e-04	-0.1885	1.1888e-02	0.1341	2.4512e-03	0.1612

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr20:33645986-33647601:+	ACC	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EER	6.8855e-04	-0.6940
ENSG00000078699.20,CBFA2T2	ACC	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EAG	6.8855e-04	-0.6940
chr20:33645986-33647601:+	BLCA	GSVA_HALLMARK_MTORC1_SIGNALING	EER	8.8364e-06	0.2692
ENSG00000078699.20,CBFA2T2	BLCA	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	2.2659e-05	0.2562
chr20:33645986-33647601:+	BRCA	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	8.4266e-13	0.2244
ENSG00000078699.20,CBFA2T2	BRCA	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	8.6391e-09	0.1812
chr20:33645986-33647601:+	CESC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	6.1194e-05	-0.2557
ENSG00000078699.20,CBFA2T2	CESC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	4.4186e-06	-0.2902
chr20:33645986-33647601:+	CHOL	GSVA_HALLMARK_COAGULATION	EER	2.0765e-02	0.4510
ENSG00000078699.20,CBFA2T2	CHOL	GSVA_HALLMARK_COAGULATION	EAG	2.0765e-02	0.4510
ENSG00000078699.20,CBFA2T2	COAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	1.0547e-05	-0.2725
chr20:33645986-33647601:+	COAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	3.6708e-03	-0.1827
chr20:33515631-33516065:+	ESCA	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	4.5682e-02	-0.3261
chr20:33495138-33495587:+	ESCA	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	4.0160e-02	0.4130
ENSG00000078699.20,CBFA2T2	ESCA	GSVA_HALLMARK_HYPOXIA	EAG	2.1574e-04	0.2876
chr20:33645986-33647601:+	ESCA	GSVA_HALLMARK_HYPOXIA	EER	4.4505e-04	0.2736
ENSG00000078699.20,CBFA2T2	GBM	GSVA_HALLMARK_SPERMATOGENESIS	EAG	2.9278e-02	-0.1884
chr20:33645986-33647601:+	GBM	GSVA_HALLMARK_SPERMATOGENESIS	EER	2.9278e-02	-0.1884
chr20:33645986-33647601:+	HNSC	GSVA_HALLMARK_P53_PATHWAY	EER	8.2836e-07	0.2595
ENSG00000078699.20,CBFA2T2	HNSC	GSVA_HALLMARK_P53_PATHWAY	EAG	3.3510e-06	0.2448
chr20:33645986-33647601:+	KIRC	GSVA_HALLMARK_DNA_REPAIR	EER	8.7063e-05	0.2203
ENSG00000078699.20,CBFA2T2	KIRC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	6.0054e-04	-0.1929
ENSG00000078699.20,CBFA2T2	KIRP	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	5.3054e-04	-0.2344
chr20:33645986-33647601:+	KIRP	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	8.6723e-04	-0.2260
ENSG00000078699.20,CBFA2T2	LAML	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	6.9298e-03	0.2376
chr20:33645986-33647601:+	LAML	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	9.8400e-03	0.2378
chr20:33645986-33647601:+	LGG	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	6.0769e-08	-0.2456
ENSG00000078699.20,CBFA2T2	LGG	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	6.0769e-08	-0.2456
chr20:33645986-33647601:+	LIHC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	5.7350e-03	0.2529
ENSG00000078699.20,CBFA2T2	LIHC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	5.7350e-03	0.2529
chr20:33645986-33647601:+	LUAD	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	2.3783e-04	0.1875
ENSG00000078699.20,CBFA2T2	LUAD	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EAG	2.8479e-04	0.1842
chr20:33645986-33647601:+	LUSC	GSVA_HALLMARK_UV_RESPONSE_UP	EER	6.1421e-09	0.2688
ENSG00000078699.20,CBFA2T2	LUSC	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	6.2921e-09	0.2686
chr20:33645986-33647601:+	MESO	GSVA_HALLMARK_MYC_TARGETS_V1	EER	1.8982e-03	0.4459
ENSG00000078699.20,CBFA2T2	MESO	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	1.8982e-03	0.4459
chr20:33495138-33495587:+	OV	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	8.1098e-03	0.4820
chr20:33645986-33647601:+	OV	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	4.4889e-11	-0.3792
ENSG00000078699.20,CBFA2T2	OV	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	7.9905e-12	-0.3925
chr20:33645986-33647601:+	PAAD	GSVA_HALLMARK_HYPOXIA	EER	5.6233e-05	0.3522
ENSG00000078699.20,CBFA2T2	PAAD	GSVA_HALLMARK_HYPOXIA	EAG	5.6233e-05	0.3522
ENSG00000078699.20,CBFA2T2	PCPG	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.1390e-04	-0.3249
chr20:33645986-33647601:+	PCPG	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	1.1390e-04	-0.3249
ENSG00000078699.20,CBFA2T2	PRAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	5.1419e-15	-0.3514
chr20:33645986-33647601:+	PRAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	4.7826e-11	-0.3001
ENSG00000078699.20,CBFA2T2	READ	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	4.2716e-03	-0.2937
chr20:33645986-33647601:+	READ	GSVA_HALLMARK_PROTEIN_SECRETION	EER	4.2060e-02	-0.2124
ENSG00000078699.20,CBFA2T2	SARC	GSVA_HALLMARK_COAGULATION	EAG	4.9533e-06	0.3269
chr20:33645986-33647601:+	SARC	GSVA_HALLMARK_COAGULATION	EER	4.9533e-06	0.3269
ENSG00000078699.20,CBFA2T2	SKCM	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	6.5890e-04	-0.1679
chr20:33645986-33647601:+	SKCM	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	6.5890e-04	-0.1679
chr20:33645986-33647601:+	STAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	5.0546e-06	-0.2362
chr20:33642463-33643514:+	STAD	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EER	2.5910e-02	0.4966
chr20:33633184-33635693:+	STAD	GSVA_HALLMARK_MTORC1_SIGNALING	EER	9.1270e-03	0.3454
ENSG00000078699.20,CBFA2T2	STAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.6162e-06	-0.2480
chr20:33515631-33516065:+	STAD	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	1.6230e-02	0.2601
chr20:33511857-33513812:+	STAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	2.7239e-02	-0.3092
chr20:33495138-33495587:+	STAD	GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING	EER	3.5347e-03	0.3167
chr20:33509197-33509758:+	STAD	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	1.1982e-02	0.3985
chr20:33645986-33647601:+	TGCT	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	7.3944e-07	-0.3950
ENSG00000078699.20,CBFA2T2	TGCT	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	7.8006e-07	-0.3942
ENSG00000078699.20,CBFA2T2	THCA	GSVA_HALLMARK_COAGULATION	EAG	1.2682e-05	0.2035
chr20:33645986-33647601:+	THCA	GSVA_HALLMARK_UV_RESPONSE_UP	EER	3.0492e-06	0.2177
ENSG00000078699.20,CBFA2T2	THYM	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	2.5971e-05	-0.4544
chr20:33645986-33647601:+	THYM	GSVA_HALLMARK_PROTEIN_SECRETION	EER	1.9575e-03	-0.3453
ENSG00000078699.20,CBFA2T2	UCEC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	3.2909e-07	-0.4300
chr20:33645986-33647601:+	UCEC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	9.9699e-07	-0.4167
ENSG00000078699.20,CBFA2T2	UVM	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	1.8909e-04	-0.4869
chr20:33645986-33647601:+	UVM	GSVA_HALLMARK_PROTEIN_SECRETION	EER	1.8909e-04	-0.4869

Top

7. Enriched editing regions and drugs for CBFA2T2

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr20:33645986-33647601:+	ACC	AZD.0530	EER	2.7187e-02	0.4930
ENSG00000078699.20,CBFA2T2	ACC	AZD.0530	EAG	2.7187e-02	0.4930
ENSG00000078699.20,CBFA2T2	BLCA	CCT007093	EAG	1.1259e-05	0.2652
chr20:33645986-33647601:+	BLCA	CCT007093	EER	1.8081e-06	0.2884
ENSG00000078699.20,CBFA2T2	BRCA	A.770041	EAG	3.8655e-08	-0.1733
chr20:33645986-33647601:+	BRCA	A.770041	EER	7.3845e-12	-0.2153
ENSG00000078699.20,CBFA2T2	CESC	BMS.536924	EAG	5.5193e-09	-0.3638
chr20:33645986-33647601:+	CESC	BMS.536924	EER	2.0717e-06	-0.3008
ENSG00000078699.20,CBFA2T2	CHOL	AS601245	EAG	5.5533e-03	0.5281
chr20:33645986-33647601:+	CHOL	AS601245	EER	5.5533e-03	0.5281
chr20:33645986-33647601:+	COAD	BIBW2992	EER	6.6009e-04	-0.2140
ENSG00000078699.20,CBFA2T2	COAD	BMS.708163	EAG	5.0709e-06	-0.2818
chr20:33515631-33516065:+	ESCA	AG.014699	EER	2.2500e-02	-0.3693
chr20:33495138-33495587:+	ESCA	Lapatinib	EER	2.0994e-02	0.4590
ENSG00000078699.20,CBFA2T2	ESCA	CGP.60474	EAG	1.9127e-07	-0.3965
chr20:33645986-33647601:+	ESCA	CGP.60474	EER	3.1464e-07	-0.3900
ENSG00000078699.20,CBFA2T2	GBM	Bortezomib	EAG	3.5342e-03	-0.2503
chr20:33645986-33647601:+	GBM	Bortezomib	EER	3.5342e-03	-0.2503
ENSG00000078699.20,CBFA2T2	HNSC	BIBW2992	EAG	1.9559e-07	-0.2730
chr20:33645986-33647601:+	HNSC	BIBW2992	EER	3.0016e-08	-0.2904
ENSG00000078699.20,CBFA2T2	KICH	Gefitinib	EAG	1.2495e-02	-0.3318
chr20:33645986-33647601:+	KICH	Gefitinib	EER	1.2495e-02	-0.3318
ENSG00000078699.20,CBFA2T2	KIRC	AZD6482	EAG	1.2754e-05	0.2447
chr20:33645986-33647601:+	KIRC	BMS.536924	EER	4.9317e-07	-0.2810
ENSG00000078699.20,CBFA2T2	KIRP	BMS.509744	EAG	2.4083e-05	-0.2837
chr20:33645986-33647601:+	KIRP	CEP.701	EER	7.7184e-04	-0.2282
ENSG00000078699.20,CBFA2T2	LAML	CHIR.99021	EAG	3.5003e-03	0.2563
chr20:33645986-33647601:+	LAML	CHIR.99021	EER	1.9248e-02	0.2162
chr20:33645986-33647601:+	LGG	JNK.Inhibitor.VIII	EER	2.7933e-08	0.2516
ENSG00000078699.20,CBFA2T2	LGG	JNK.Inhibitor.VIII	EAG	2.7933e-08	0.2516
ENSG00000078699.20,CBFA2T2	LIHC	Cyclopamine	EAG	3.3726e-02	-0.1999
chr20:33645986-33647601:+	LIHC	Cyclopamine	EER	3.3726e-02	-0.1999
chr20:33645986-33647601:+	LUAD	CI.1040	EER	1.5834e-05	-0.2195
ENSG00000078699.20,CBFA2T2	LUAD	CI.1040	EAG	1.1999e-05	-0.2213
ENSG00000078699.20,CBFA2T2	LUSC	CCT007093	EAG	9.3356e-05	0.1825
chr20:33645986-33647601:+	LUSC	CCT007093	EER	9.9870e-05	0.1818
ENSG00000078699.20,CBFA2T2	MESO	CMK	EAG	5.0889e-03	-0.4062
chr20:33645986-33647601:+	MESO	CMK	EER	5.0889e-03	-0.4062
chr20:33645986-33647601:+	OV	Embelin	EER	2.9713e-11	0.3824
ENSG00000078699.20,CBFA2T2	OV	Embelin	EAG	1.0087e-11	0.3908
ENSG00000078699.20,CBFA2T2	PAAD	AUY922	EAG	8.4588e-04	-0.2948
chr20:33645986-33647601:+	PAAD	AUY922	EER	8.4588e-04	-0.2948
ENSG00000078699.20,CBFA2T2	PCPG	JNJ.26854165	EAG	6.5174e-07	-0.4114
chr20:33645986-33647601:+	PCPG	JNJ.26854165	EER	6.5174e-07	-0.4114
ENSG00000078699.20,CBFA2T2	PRAD	BMS.509744	EAG	3.3753e-15	-0.3536
chr20:33645986-33647601:+	PRAD	BMS.509744	EER	2.9897e-10	-0.2879
ENSG00000078699.20,CBFA2T2	READ	AZD6244	EAG	1.5040e-05	-0.4346
chr20:33645986-33647601:+	READ	ATRA	EER	3.2222e-03	0.3040
chr20:33645986-33647601:+	SARC	BMS.536924	EER	1.3256e-09	-0.4251
ENSG00000078699.20,CBFA2T2	SARC	BMS.536924	EAG	1.3256e-09	-0.4251
ENSG00000078699.20,CBFA2T2	SKCM	BMS.509744	EAG	5.9940e-09	-0.2829
chr20:33645986-33647601:+	SKCM	BMS.509744	EER	5.9940e-09	-0.2829
chr20:33645986-33647601:+	STAD	CI.1040	EER	5.4901e-07	-0.2586
chr20:33633184-33635693:+	STAD	BAY.61.3606	EER	5.1807e-03	0.3686
chr20:33515631-33516065:+	STAD	BIRB.0796	EER	5.7684e-03	-0.2970
chr20:33642463-33643514:+	STAD	FTI.277	EER	1.4280e-02	-0.5386
chr20:33518600-33520634:+	STAD	Docetaxel	EER	8.4857e-03	-0.4507
ENSG00000078699.20,CBFA2T2	STAD	CI.1040	EAG	3.2518e-07	-0.2635
chr20:33495138-33495587:+	STAD	CI.1040	EER	4.0449e-02	-0.2254
chr20:33511857-33513812:+	STAD	GSK269962A	EER	7.7610e-03	-0.3687
chr20:33645986-33647601:+	TGCT	AZ628	EER	1.6092e-06	-0.3837
ENSG00000078699.20,CBFA2T2	TGCT	AZ628	EAG	1.5305e-06	-0.3844
ENSG00000078699.20,CBFA2T2	THCA	Embelin	EAG	3.2996e-29	0.4937
chr20:33645986-33647601:+	THCA	Embelin	EER	2.4900e-11	0.3075
ENSG00000078699.20,CBFA2T2	THYM	AZD6482	EAG	2.3104e-09	0.6106
chr20:33645986-33647601:+	THYM	AZD6482	EER	1.5794e-06	0.5129
ENSG00000078699.20,CBFA2T2	UCEC	GDC.0449	EAG	1.0683e-05	-0.3756
chr20:33645986-33647601:+	UCEC	JNK.9L	EER	1.1518e-07	0.4479
chr20:33645986-33647601:+	UCS	BMS.754807	EER	1.9603e-02	-0.3589
ENSG00000078699.20,CBFA2T2	UCS	BMS.754807	EAG	1.9597e-02	-0.3589
ENSG00000078699.20,CBFA2T2	UVM	ABT.263	EAG	1.7366e-03	0.4164
chr20:33645986-33647601:+	UVM	ABT.263	EER	1.7366e-03	0.4164

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType